• Prevalence of Lynch syndrome in women with endometrial cancer
    Prevalence of Lynch syndrome in women with endometrial cancer

    Analysis of data from 12,633 patients with endometrial cancer.

  • Cervical cancer: no survival benefit for ACT after concurrent chemoradiation

    Findings from ACTLACC trial.

  • Ovarian cancer: add-on trebananib fails to delay progression in phase 3

    Data from the multinational TRINOVA-3 trial.

  • Tubal ligation is not associated with early natural menopause

    Surgical sterilization is one of the most common methods of contraception in the US.

  • Meta-analysis: safety of immune checkpoint inhibitors in cancer

    Large meta-analysis of 125 studies, 20k patients.

  • Salpingectomy at the time of permanent contraception: rates have increased

    Future rates of ovarian cancer may reflect success of this procedure.

  • Ovarian cancer: intraperitoneal chemotherapy ineffective in definitive trial

    Intraperitoneal administration shows no survival advantage, increases toxicity in GOG-252.

  • Cervical cancer: chemoradiation with doublet tops monotherapy in meta-analysis

    Platinum-based doublet therapy was less tolerable.

  • Early endometrial cancer: vaginal brachytherapy+chemo no better than pelvic RT

    Pelvic RT alone remains an effective and well-tolerated adjuvant treatment.

  • Cervical cancer: HDR brachytherapy effective with less toxicity

    Similar local disease control, cancer-specific survival vs LDR brachytherapy.

  • The impact of the HSCA on cervical cancer screening rates

    Exploring the impacts of the 2012 Health and Social Care Act reforms on clinical activity in the English NHS.

  • Northern Ireland's health department makes two major health protection declarations
    Northern Ireland's health department makes two major health protection declarations

    Announcements pertaining to HPV vaccination and bowel screening.

  • ECCMID 2019 - Cancer chemotherapy drives antimicrobial resistance by disrupting the gut microbiome

    By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.

  • Cervical cancer: cetuximab fails phase 2 in advanced/recurrent disease

    PIK3CA mutation status predicted resistance to cetuximab.

  • Therapeutic vaccine targets HPV, clears cervical cancer precursors

    Phase 2 trial shows efficacy regardless of high-risk HPV type.

  • Cervical cancer: the study behind FDA approval of pembrolizumab

    Data from the phase 2 pembrolizumab KEYNOTE-158 basket study.

  • AACR 2019—​​​​​​​HPV vaccination rates low in adults at high risk for HIV

    HIV coinfection increases HPV-related cancer risk.

  • Load more